NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced results of an industry survey to better understand how global life sciences companies think about and use data in clinical research. Conducted in partnership with PharmaVOICE magazine and titled “Using Data and Analytics in Clinical Development,” the survey revealed that 90% of respondents rely on some form of analytics solution—viewing data as a critical element for achieving their R&D priorities—but are limited to their own data to make strategic decisions.
Garnering insights from nearly 200 life sciences executives across pharmaceutical companies, contract research organizations (CROs), biotech companies and medical device developers, the survey indicated that reducing clinical research timelines was the number one concern to their business, regardless of company size, and that three key challenges stand in the way of achieving shorter timelines and overall R&D goals:
- Patient recruitment: 70% of trials are delayed by more than one month, and recruitment is the leading cause. Such drawn out timelines quickly escalate costs. Further, today’s current approach to recruitment puts the onus on investigators, whose training and focus is on treating patients, not recruiting tactics. Such an issue calls for a solution that relies on an ecosystem of data, analytics, technology, services and provider organizations.
- Data quality: Since 2000, the number of participating trial sites outside of the US has doubled, and the breadth of clinical information has expanded to include data from electronic data capture (EDC) systems, medical imaging, labs, electronic health records (EHR), genomics and biomedical sensors. The inbound volume and rate of such data sets are exponentially larger than traditional clinical data; as such, old methods of capturing, cleaning and analyzing are becoming antiquated. As the industry shifts from static to adaptive data management, leveraging machine learning and advanced algorithms (to identify statistical relationships and outliers) is paramount.
- Patient retention: Patient drop-out in clinical studies today is estimated to be around 18%, while the cost of recruiting a patient is 12 times greater than those associated with proper engagement tactics to retain them. The introduction of mobile health (mHealth) tools are encouraging more patient-centric research practices—alleviating patient burden and improving compliance and retention. Further, integrated technology platforms, such as mobile apps built on an EDC system, not only create a single source of truth; they enable sponsors to push data back to patients for ongoing feedback loops and communications between researchers and patients.
While respondents’ general data needs differ based on organizational type, roles and size, the survey indicated that real-world evidence (RWE) and historical trial data are the two most sought-after data sets. This is likely attributed to the cost and time-saving implications of leveraging such data during study design and execution. Real-world clinical and commercial data can increase the speed and accuracy of clinical trial site selection, patient recruitment and cohort generation, while tapping into patient-level data from historical clinical trials offer the possibility of early insight during clinical development and reduced failure rates in Phase II and III studies.
“The volume of data in healthcare is growing at a massive rate, as the industry enters the exciting realm of RWE, genomics, historical control arms and high-frequency sensor data. But such data yields valuable insight only if it is properly integrated, standardized and analyzed,” said David Lee, Medidata’s chief data officer. “Fortunately, sponsors and CROs are increasingly partnering with technology companies that specialize in integrating new data sources, leveraging machine learning and deploying data science solutions into clinical development workflows. These innovations are already streamlining manual, resource-intensive processes and accelerating timelines to key operational and scientific milestones. Re-architecting pharmaceutical business models to optimize use of data-driven insights will increase the success rate of clinical trials and help improve patients’ lives.”
For more information on leveraging analytics to improve decision-making, lower R&D costs and shorten clinical research timelines, join Medidata and SHYFT Analytics for our joint webinar on June 28, “7 Ways to Compress Your Clinical Trial Timeline.”
To download the full eBook with detailed survey results, visit here.
Connect with Medidata
Read our blog, Geeks
Tweet this: New survey conducted by @Medidata & @PharmaVOICE reveals #data wants, needs & opportunities in #clinicalresearch: http://ow.ly/bWtK30cLmiv
Follow us on Twitter: @Medidata
Find us on LinkedIn
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.